Kawashima Mitsuaki, Ijiri Naohiro, Konoeda Chihiro, Toyokawa Gouji, Nakao Keita, Cong Yue, Hino Haruaki, Kurosawa Hideo, Kashiwa Koichi, Ushio Michiko, Kawamura Gaku, Ando Masahiko, Shimada Shogo, Ono Minoru, Sato Masaaki
Department of Thoracic Surgery, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Organ Transplantation Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Eur J Cardiothorac Surg. 2025 Aug 2;67(8). doi: 10.1093/ejcts/ezaf256.
Lung transplantation (LTx) for patients with pulmonary arterial hypertension (PAH) is associated with high postoperative morbidity and mortality. Extracorporeal membrane oxygenation (ECMO) supports patients' haemodynamics during and after LTx. However, the optimal ECMO strategy, especially for patients with PAH, is debated. Here, we report our unique strategy for patients with PAH, using postoperative central veno-arterial (VA)-ECMO combined with delayed chest closure.
This was a retrospective single-centre study of consecutive bilateral lung transplantations for adult patients with PAH performed between 2021 and 2024. Patients' characteristics, perioperative ECMO strategy, and postoperative outcomes were reviewed.
During the study period, 20 PAH patients (idiopathic or hereditary PAH [n = 17], PAH secondary to collagen disease [n = 1], pulmonary veno-occlusive disease [n = 1], and Eisenmenger syndrome [n = 1]) underwent cadaveric LTx. Intraoperative support comprised either central VA-ECMO (n = 17) or cardiopulmonary bypass (n = 3). In 17 patients, central VA-ECMO was maintained postoperatively with temporary skin closure. The reason for postoperative central VA-ECMO was anticipated post-LTx heart failure due to PAH and suboptimal cardiac function. The median duration of ECMO support was 4 days (interquartile range: 2-4). There were 9 (45.0%) haemothorax evacuations while patients were on postoperative central VA-ECMO. No patients experienced haemodynamic collapse after LTx. All patients survived during the observation period, resulting in a 100% survival rate at both 90 days and 1 year (95% confidence interval: 83.2%-100%).
Extended postoperative central VA-ECMO and delayed chest closure were feasible for patients with PAH who underwent LTx. Meticulous haemostasis is mandatory, given the high chance of haemothorax evacuation.
肺动脉高压(PAH)患者的肺移植(LTx)术后发病率和死亡率较高。体外膜肺氧合(ECMO)在LTx术中及术后维持患者的血流动力学。然而,最佳的ECMO策略,尤其是针对PAH患者的策略,仍存在争议。在此,我们报告我们针对PAH患者的独特策略,即术后采用中心静脉 - 动脉(VA)-ECMO联合延迟关胸。
这是一项回顾性单中心研究,研究对象为2021年至2024年间连续接受双侧肺移植的成年PAH患者。回顾了患者的特征、围手术期ECMO策略和术后结局。
在研究期间,20例PAH患者(特发性或遗传性PAH [n = 17]、胶原病继发PAH [n = 1]、肺静脉闭塞病 [n = 1] 和艾森曼格综合征 [n = 1])接受了尸体供肺LTx。术中支持包括中心VA-ECMO(n = 17)或体外循环(n = 3)。17例患者术后采用临时皮肤缝合维持中心VA-ECMO。术后采用中心VA-ECMO的原因是预计LTx后因PAH和心功能欠佳导致心力衰竭。ECMO支持的中位持续时间为4天(四分位间距:2 - 4天)。术后患者接受中心VA-ECMO期间有9例(45.0%)进行了血胸引流。LTx术后无患者发生血流动力学崩溃。所有患者在观察期内均存活,90天和1年生存率均为100%(95%置信区间:83.2% - 100%)。
对于接受LTx的PAH患者,延长术后中心VA-ECMO和延迟关胸是可行的。鉴于血胸引流的可能性较大,细致的止血措施必不可少。